alydiahealth Archives - Medical Design Sourcing

Merck spinoff Organon completes Alydia Health acquisition

Merck (NYSE: MRK) spinoff Organon (NYSE:OGN) today announced the completion of its acquisition of Alydia Health for up to $240 million.

Alydia Health develops treatments centered around preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding. The company designed its Jada system to control and treat abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.

Jersey City, N.J.-based Organon announced an agreement for the acquisition in March. Total consideration amounts to $240 million, including a $215 million cash payment, of which Merck paid $50 million upon signing. Organon paid the remaining $165 million at closing and the final $25 million will potentially arrive as a contingent milestone payment.

“Organon’s acquisition of Alydia Health expands our portfolio into the medical device category and underscores our commitment to identify options for women’…

Alydia Health appoints VP of sales

Alydia Health this week said it has appointed Paul Praino as its VP of sales.

Praino will be responsible for expanding the company’s sales efforts for the Jada System, Alydia Health’s device that is designed to encourage normal contraction of the uterus to rapidly stop excessive bleeding after childbirth.

“Paul is an experienced commercial sales leader who is skilled at hiring, developing and motivating his team to meet the scalability needs of high-growth organizations and deliver sales results,” CEO Rob Binney said in a news release. “As we prepare to join Organon and build a high-performing medical device sales organization, we believe Paul is the right person to lead the acceleration of the Jada System launch to more hospitals and patients across the U.S.”

Priano has more than 15 years of experience in medical device sales. He most recently served as global VP of sales at Intersect ENT. He has also held numerous leadership roles at Access…

Merck spinoff Organon to acquire Alydia Health for up to $240M

Merck announced today that it entered into an agreement for its spinoff Organon to acquire Alydia Health for up to $240 million.

Alydia Health develops treatments focusing on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding, according to a news release. The company develops the Jada system for controlling and treating abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.

The deal is slated to close after Organon has successfully spun off from Merck as a standalone, publicly-traded company, a move expected to be completed late in the second quarter of 2021.

Organon’s agreement to acquire Alydia Health includes up to $240 million total consideration, with $215 million being spent upfront, plus a $25 million contingent milestone payment. Of the upfront payment, $50 million will be paid prior to Organon’s spinoff, with the remaining $1…